Public Employees Retirement System of Ohio Sells 1,248 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Public Employees Retirement System of Ohio reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,166 shares of the biotechnology company’s stock after selling 1,248 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $4,403,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in UTHR. Blue Trust Inc. raised its holdings in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. MBM Wealth Consultants LLC raised its stake in shares of United Therapeutics by 2.7% in the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of United Therapeutics by 1.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock worth $856,000 after acquiring an additional 61 shares during the last quarter. Janiczek Wealth Management LLC boosted its stake in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares during the period. Finally, Compass Ion Advisors LLC grew its holdings in United Therapeutics by 3.6% during the 1st quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 101 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $259.70, for a total transaction of $934,920.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $33,761. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 100,884 shares of company stock valued at $30,280,055. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 7.2 %

NASDAQ UTHR opened at $313.29 on Thursday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $343.98. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The company has a market capitalization of $13.90 billion, a price-to-earnings ratio of 14.81, a price-to-earnings-growth ratio of 1.09 and a beta of 0.55. The company’s 50-day simple moving average is $306.21 and its two-hundred day simple moving average is $259.74.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% compared to the same quarter last year. During the same period last year, the company posted $4.86 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 25.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. The Goldman Sachs Group boosted their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $330.64.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.